Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 5
Submit an article Journal homepage
19
Views
1
CrossRef citations to date
0
Altmetric
Drug Evaluation

Idiopathic- and scleroderma-related pulmonary arterial hypertension: outcomes and QOL on bosentan

Anne Keogh St Vincent’s Hospital, Xavier 4, Victoria St, Darlinghurst, Sydney, NSW 2010, Australia. [email protected]
&
John Wlodarczyk Consulting Services, 10 Mirral Close, New Lambton, NSW 2305, Australia. [email protected]
Pages 505-513 | Published online: 09 Jan 2014

References

  • Channick RN, Simonneau G, Sitbon O et aL Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358, 1119–1123 (2001).
  • ••Randomized placebo-controlled study ofbosentan therapy for the treatment of pulmonary arterial hypertension (PAH).
  • Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl. J. Med. 346, 896–903 (2002).
  • ••Randomized placebo-controlled study ofbosentan therapy for the treatment of PAH.
  • Keogh A, Macdonald P, Williams T et al. Tracleer® (Bosentan) for the treatment of pulmonary arterial hypertension (PAH) — 6 month quality of life data. Heart Lung & Circulation (2004) (In Press).
  • ••Randomized placebo-controlled study ofbosentan therapy for the treatment of PAH.
  • McLaughlin V, Sitbon O, Rubin LJ et aL The effects of first-line bosentan on survival of patients with primary pulmonary hypertension. Am. J Resp. Crit. Care Med. 167,442 (2003).
  • •Survival data on bosentan therapy for the treatment of PAH.
  • Galiè N, Hinderliter AL, Torbicki A et aL Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am. Coll. CardioL 41,1380–1386 (2003).
  • Owens DK. Interpretation of cost- effectiveness analyses. J. Gen. Intern. Med. 13(10), 716–717 (1998).
  • Towse A. What is NICE's threshold? An external view. In: Cost Effectiveness Thresholds: Economic and Ethical Issues. Devlin N, Towse A (Eds). Kings Fund/ Office for Health Economics, London, UK (2002).
  • George B, Harris A, Mitchell A. Cost- effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). PharmacoEconomics 19(11), 1103–1109 (2001).
  • Koh ET, Lee P, Gladman DD, Abu-Shaltra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. J. Rheum. 35,989-993 (1996).
  • MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumotology40, 453–459 (2001).
  • Galfe N, Manes A, Uguccioni L et al. Primary pulmonary hypertension; insights into the pathogenesis from epidemiology. Chest 114, S184—S194 (1998).
  • Game SP, Rubin U. Primary pulmonary hypertension. Lancet 352,719–725 (1998).
  • British Cardiac Society Guidelines. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 86(Supp. I), I1—I13 (2001).
  • Keogh AM, McNeil KD, Williams T, Gabbay E, Cleland LG. Pulmonary arterial hypertension: a new era in management. Med. J. Aust. 178,564-567 (2003).
  • Fowler N, Wescott R, Scott R. Normal pressure in right heart and pulmonary artery. Am. Heart J 46,264–270 (1953).
  • Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70(4), 580–587 (1984).
  • Kim NHS, Rubin U. Endothelin in Health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J. Cardiovasc. PharmacoL Therapeut. 7(1), 9–19 (2002).
  • Hoeper MM, Gaffe N, Simonneau G, Rubin U. New treatments for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 165,1209–1216 (2002).
  • Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature332, 411–415 (1988).
  • Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. I MoL Med. 77,364–376 (1999).
  • Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert. Opin. Investig. Drugsll (7), 991–1002 (2002).
  • Krum H, Liew D. Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. CUIT: Opin. Investig. Drugs 4(3) 298–302 (2003).
  • Lane K, Machado R, Pauciulo M et al. Heterozygous germline mutations in BMPR2, encoding a TGF-B receptor, cause familial primary pulmonary hypertension. Nature Genetics 26,81–84 (2000).
  • D'Alonzo G, Barst R, Ayres S et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. 115(5), 343–349 (1991).
  • Nagaya N, Nishikimi T, Venetsu M et al. Plasma brain naturetic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102,865–870 (2000).
  • Miyamoto S, Nagaya N, Satoh T et aL Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 161,487–492 (2000).
  • Chua R, O'Loughlin A, Keogh A, Brown K, Corrigan C. Comparison and validation of three quality of life instruments for the functional assessment of pulmonary arterial hypertension. J. Heart Lung Transplant. 23, 5143 (2004).
  • Gabbay E, McNeil K, William T, Wlodarczyk J, Seale H, Keogh A. Tracleer® (bosentan) therapy in patients with pulmonary arterial hypertension: the relationship between improvements in six-minute walk test (6MWT) and quality of life (Q0L). American Thoracic Society 100th International Conference. FL, USA, (2004).
  • Wight JP, Edwards L, Brazier J, Waters S, Payne JN, Brown CB. The SF-36 as an outcome measure of services for end stage renal failure. QuaL Healthcare 7(4), 209–221 (1998).
  • Harper R, Brazier JE, Waterhouse JC, Walters SJ, Jones NM, Howard P. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax52(10), 879–887 (1997).
  • Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomised, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Arn Heart J. 124(4), 1017–1025 (1992).
  • McKenna S, Doughty N, Pepke-Zaba J. Qualitative patient interviews demonstrate the need to develop quality of life (Q0L) and health-related quality of life (HRQL) measures specific to pulmonary arterial hypertension. PAH Symposium JACC 2003 (2004) (In Press).
  • Rich S, Brundage B, Levy P. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation71 (6), 1191–1196 (1985).
  • Sitbon O, Humbert M, loos V et al Who benefit from long-term calcium-channel blacker (CCB) therapy in primary pulmonary hypertension (PPH). American Thoracic Society 99th International Conference. WA, USA, A440 (2003).
  • Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl. J. Med. 334(5), 296–302 (1996).
  • McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (12), 1477–1482 (2002).
  • Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40(4) 780–788 (2002).
  • Hoeper M, Schwaze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolised iloprost, a prostacyclin analogue. N Engl. J. Med. 342,1866–1870 (2000).
  • Galfe N, Humbert M, Vachiery J-L et al. Effects of beraprost sodium an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J. Am. Coll. Cardiol. 39, 1496–1502 (2002).
  • Olschewski H, Simmonneau G, Galfe N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl. J. Med. 347(5), 322–329 (2002).
  • Sastry BK, Narasimhan C, Reddy NK et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J. 54(4), 410–414 (2002).
  • Humbert M, Simonneau S. Sildenafil for pulmonary arterial hypertension. Still waiting for evidence. Am. J. Resp. Crit. Care Med. 169,6–7 (2004).
  • Cooper DA, Macdonald PS, Sitbon O et aL Bosentan treatment in patients with pulmonary arterial hypertension associated with HIV infection. 15th Annual Conference of the Australasian Society for HIV Medicine (ASHM). Cairns, Australia (2003).
  • Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99, 1197–1208 (1999).
  • Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123, 344–350 (2003).
  • Bedi M, Spates-Panyon J, Mathier M et al. Long-term survival comparison in patients with primary and secondary pulmonary arterial hypertension treated with chronic epoprostenol therapy. 52nd Annual Scientific Conference of the American College of Cardiology Chicago, USA (2003).
  • Policy Analysis, Inc. Exploratory Analyses of Data from BREATHE-1 on Measures of Potential Pharmacoeconomic Significance. Brookline, Mass. (2001).
  • Highland K, Strange C, Mazur J, Simpson K. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 124,2087–2092 (2003).
  • ••Comparative model of survival, costs andquality of life in treatments for PAH.
  • Keogh A, Brown K, Corrigan C, Allada C, Ten Y. The effect of open-label UT15 and bosentan on hospitalisation rate in patients with pulmonary arterial hypertension. J. Heart Lung Transplant. 21,159 (2002).
  • •Comparative data on hospitalization rates in two treatments for PAH.
  • Humbert M, Barst RJ, Robbins IM et aL Safety 8z efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension. American Thoracic Society 99th International Conference. Seattle USA, A441 (2003).
  • Barst RJ, Ivy D, Dingemanse J et aL Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 73(4), 372–382 (2003).
  • Hopman WM, Towheed T, Anastassiades T et al. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ 163(3), 265–271 (2000).

Website

  • World Health Organization. Primary pulmonary hypertension: executive summary from the World Symposium — primary pulmonary hypertension 1998. Rich S (Ed.). (1998) www.who.intincd/cvdipph.html (Accessed September 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.